AstraZeneca PLC

LSE:AZN 株式レポート

時価総額：UK£179.3b

AstraZeneca 将来の成長

Future 基準チェック /46

AstraZeneca利益と収益がそれぞれ年間13.7%と6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に28.4% 14.5%なると予測されています。

主要情報

13.7%

収益成長率

14.54%

EPS成長率

Pharmaceuticals 収益成長12.2%
収益成長率6.0%
将来の株主資本利益率28.40%
アナリストカバレッジ

Good

最終更新日17 Aug 2026

今後の成長に関する最新情報

Recent updates

ナラティブ更新 • Aug 13

AZN: Pipeline Strength And 2030 Revenue Ambition Will Drive Re Rating

Analysts have trimmed AstraZeneca's fair value estimate to £189.66 from £200.76, reflecting slightly higher assumed discount rates and more cautious long-term revenue growth expectations, partly informed by recent mixed trial outcomes and Street price target revisions. Analyst Commentary Recent Street commentary on AstraZeneca highlights a mix of caution around specific trial setbacks and corporate scenarios, along with continued confidence in the broader pipeline, execution, and long term growth ambition.
ナラティブ更新 • Jul 30

AZN: Oncology Approvals And Pipeline Progress Will Support Future Repricing

Analysts have trimmed their AstraZeneca price targets, with the modelled fair value easing from £164.85 to £159.11. This reflects slightly lower assumptions for revenue growth, profit margin and future P/E following recent trial setbacks and updated Street research.
ナラティブ更新 • Jul 16

AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility

AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.
ナラティブ更新 • Jul 02

AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating

Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.
分析記事 • Jun 19

AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback

AstraZeneca (LSE:AZN) is back in focus after recent share price pressure, with the stock down about 5% over the past month and past 3 months. This has prompted investors to reassess its long term profile. See our latest analysis for AstraZeneca. Despite the recent share price decline, with the stock down 5.3% on a 90 day share price return basis and currently trading at £131.54, AstraZeneca still shows a 73.7% total shareholder return over five years. This suggests long term holders have seen...
ナラティブ更新 • Jun 18

AZN: New Approvals And AI Use Will Support Future Repricing

The latest narrative update on AstraZeneca reflects a modest trimming of the analyst fair value estimate to £164.85, as analysts factor in updated revenue growth and profit margin assumptions following recent price target increases and ongoing commentary around the company’s drug pipeline and regulatory outcomes. Analyst Commentary Recent Street research around AstraZeneca centers on how regulators and pricing decisions may affect the company’s growth options, as well as how advisory outcomes could influence execution risk in parts of its pipeline.
ナラティブ更新 • Jun 03

AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing

Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.
ナラティブ更新 • Apr 29

AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing

AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.
ナラティブ更新 • Apr 15

AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating

Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.
ナラティブ更新 • Apr 01

AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations

AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.
ナラティブ更新 • Mar 18

AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating

Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.
ナラティブ更新 • Mar 03

AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook

The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.
ナラティブ更新 • Feb 17

AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks

Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.
ナラティブ更新 • Feb 03

AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook

Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.
ナラティブ更新 • Jan 20

AZN: Oncology Pipeline And 2030 Sales Ambition Will Support Re Rating

Narrative Update The analyst price target for AstraZeneca has been nudged higher to reflect a fair value estimate of £182.81 per share, with analysts pointing to supportive Street research that includes recent target upgrades from Deutsche Bank and Barclays, as well as constructive commentary on oncology and the broader biopharma pipeline. Analyst Commentary Recent Street research reflects a cluster of bullish analysts lifting price targets on AstraZeneca, with several pointing to oncology and the broader biopharma pipeline as key parts of their constructive view.
ナラティブ更新 • Jan 06

AZN: Oncology And Biopharma Execution Will Offset Patent Pressure Concerns

AstraZeneca's implied fair value has shifted from £173.72 to £182.32 as analysts weigh stronger confidence in oncology and broader biopharma sales potential against concerns about approaching patent pressures and a less certain pipeline in breast cancer. Analyst Commentary Recent research shows a split in views, but bullish analysts see room for AstraZeneca's valuation to reflect stronger confidence in oncology and biopharma execution, even as others flag upcoming patent risks and breast cancer pipeline uncertainty.

業績と収益の成長予測

LSE:AZN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202871,30115,66814,46120,69121
12/31/202766,85213,71612,97218,84124
12/31/202663,25112,0709,41816,49624
6/30/202661,36610,4466,25013,700N/A
3/31/202660,43910,3897,91914,221N/A
12/31/202558,73910,2258,80614,575N/A
9/30/202558,1279,3999,67915,140N/A
6/30/202556,5018,2958,32713,389N/A
3/31/202554,9827,7729,19513,088N/A
12/31/202454,0737,0357,39811,861N/A
9/30/202451,2066,4956,86711,334N/A
6/30/202449,1336,4407,04511,065N/A
3/31/202447,6116,3315,8879,698N/A
12/31/202345,8115,9556,85810,345N/A
9/30/202344,9945,8967,27010,363N/A
6/30/202344,4856,1636,85410,179N/A
3/31/202343,8404,7056,3579,709N/A
12/31/202244,3513,2887,6849,808N/A
9/30/202245,1552,0406,5388,828N/A
6/30/202244,038-1,2535,7897,617N/A
3/31/202241,487-1,0635,7217,261N/A
12/31/202137,4171124,3505,963N/A
9/30/202132,8161,4715,1846,343N/A
6/30/202129,5283,7715,4216,446N/A
3/31/202127,5833,9774,8996,594N/A
12/31/202026,6173,1963,1444,799N/A
9/30/202025,8712,4973,2734,376N/A
6/30/202025,6992,1483,0573,657N/A
3/31/202025,2471,522N/A3,495N/A
12/31/201924,3841,335N/A2,969N/A
9/30/201924,1372,056N/A3,818N/A
6/30/201923,0712,188N/A3,184N/A
3/31/201922,4032,408N/A2,371N/A
12/31/201822,0902,155N/A2,618N/A
9/30/201821,4502,422N/A1,391N/A
6/30/201822,3422,677N/A3,165N/A
3/31/201822,2382,804N/A3,350N/A
12/31/201722,4653,001N/A3,578N/A
9/30/201722,2733,542N/A4,541N/A
6/30/201721,7403,870N/A3,109N/A
3/31/201722,2923,390N/A3,040N/A
12/31/201623,0023,499N/A4,145N/A
9/30/201623,8162,465N/A2,756N/A
6/30/201624,0622,221N/A3,690N/A
3/31/201624,7662,921N/A4,589N/A
12/31/201524,7082,825N/A3,324N/A
9/30/201525,0251,696N/A4,595N/A

アナリストによる今後の成長予測

収入対貯蓄率: AZNの予測収益成長率 (年間13.7% ) は 貯蓄率 ( 3.6% ) を上回っています。

収益対市場: AZNの収益 ( 13.7% ) はUK市場 ( 11.6% ) よりも速いペースで成長すると予測されています。

高成長収益: AZNの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: AZNの収益 ( 6% ) UK市場 ( 4% ) よりも速いペースで成長すると予測されています。

高い収益成長: AZNの収益 ( 6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AZNの 自己資本利益率 は、3年後には高くなると予測されています ( 28.4 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/18 17:59
終値2026/08/18 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

AstraZeneca PLC 24 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。56

アナリスト機関
null nullABG Sundal Collier
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research